Login to Your Account

Interchangeable would be game changer for Humira competition

By Mari Serebrov
Regulatory Editor

Monday, July 11, 2016

A double-header this week in which the FDA's Arthritis Advisory Committee (AAC) will be looking at potential biosimilars for two more TNF-inhibitors is creating a lot of buzz about when biosimilar competition for Humira and Enbrel will hit the U.S. market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription